Dataset Information

Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients.

ABSTRACT:

Background

Diagnosis and management of neuropathic pain (NP) in foot and ankle patients remain challenging. We investigated the plausibility of using Patient-Reported Outcomes Measurement Information System (PROMIS) Neuropathic Pain Quality (PQ-Neuro) as an initial screening tool to detect NP and track the treatment effects.

Methods

Patients with heel pain were prospectively recruited and grouped to no-NP, mild-NP, and severe-NP based on the initial PROMIS PQ-Neuro t scores. Pain Interference (PI), Physical Function (PF), and Self-Efficacy (SE) scores were evaluated at baseline, 30-day, and 90-day follow-up. Other factors such as age, smoking, body mass index (BMI), low back/neck pain, anxiety/depression, and medications were analyzed. Linear mixed modeling was used to assess the main effects of time and NP on PROMIS t scores, comparing minimal clinically important difference (MCID).

Results

Forty-eight patients with mean age of 52.4 years were recruited. Using the PROMIS PQ-Neuro as the assessment tool, 33 patients (69%) were detected to have NP at baseline-23 (48%) mild and 10 (21%) severe. BMI was the only independent factor associated with NP (P = .011). Higher baseline PQ-Neuro t score was significantly associated with higher follow-up PQ-Neuro (P < .001), PI (P = .005), and lower SE (P = .04) across time points. Patients with NP showed lower PF at baseline with significantly less improvement in PF (3 vs 9.9, P = .035) and did not meet MCID.

Conclusion

Baseline PROMIS PQ-Neuro ≥46 was significantly associated with worse PI and SE across all time points, with less clinically significant improvements in PF. Prevalence of NP in heel pain patients was high. The PROMIS PQ-Neuro may serve as a valuable tool for detection of NP and guiding clinical treatment decision pathways for heel pain patients.

Level of evidence

Level III, prospective cohort study.

SUBMITTER: Joo PY

PROVIDER: S-EPMC10697051 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients.

Joo Peter Y PY Lee Wonyong W Hoffman Samantha S Baumhauer Judith J Oh Irvin I

Foot & ankle orthopaedics 20231001 4

<h4>Background</h4>Diagnosis and management of neuropathic pain (NP) in foot and ankle patients remain challenging. We investigated the plausibility of using Patient-Reported Outcomes Measurement Information System (PROMIS) Neuropathic Pain Quality (PQ-Neuro) as an initial screening tool to detect NP and track the treatment effects.<h4>Methods</h4>Patients with heel pain were prospectively recruited and grouped to no-NP, mild-NP, and severe-NP based on the initial PROMIS PQ-Neuro <i>t</i> scores ...[more]

PMID: 38058978

Similar Datasets

Project description:Background contextPatients with mechanical chronic lower back pain (CLBP) have few durable treatment options for their condition and thus suffer decreased productivity and have higher healthcare resource utilization (HRU) compared to patients without CLBP. The economic burden of treatment and ongoing care for CLBP is considerable, with healthcare spending in 2016 estimated at $134.5 billion in the United States.PurposeThis study aims to assess the correlation between patient-reported physical function scores and HRU in patients treated for mechanical CLBP.Study designThis was a retrospective cohort study within a university-based health system.Patient samplePatients with a diagnosis of mechanical CLBP from 2015 through 2020 (index date) who were non-surgical candidates at baseline were included in this study. To ensure the presence of chronic low back pain, patients were required to have encounters between 6 and 12 months as well as between 12 and 24 months following the date of CLBP diagnosis.Outcome measuresCollected data variables included patient baseline characteristics, Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) scores, pharmacologic and non-pharmacologic therapies, HRU, and healthcare charges between January 2015 through December 2022.MethodsPROMIS-PF scores were converted to numerical categories ranging from 0 to 3, with Category 0 representing the lowest physical function and Category 3 the highest physical function. Patients were more broadly stratified into Low Physical Function (Low-PF) (Category 0-1) or High-Physical Function(High-PF) (Category 2-3) cohorts. HRU was compared between the Low-PF and High-PF cohorts using linear regression analyses. A mixed-effects regression analysis comparing Low-PF and High-PF patients was performed to model the relationship between patient-reported physical function and healthcare charges. The model is able to estimate charges for a base-case patient and can be adjusted to include patient-specific characteristics.ResultsA total of 2765 patients were included in this study, mean age was 50.1 (SD:17.7) years old, 23.6 % were 65 years or older, 68.4 % were female, and 85.3 % were white. Median healthcare charges by PROMIS-PF categories for Year-1 were highest for Category 0 patients ($14,028 [IQR: $5190-38,289]) and lowest for Category 3 ($5352 [IQR: $2417-14,470]). Patients in the Low-PF cohort showed significantly higher rates of all-cause, inpatient stays, outpatient visits, and emergency department (ED) visits compared to High-PF patients. The mixed effects regression model estimated cumulative healthcare charges to be > 2-fold higher for a base-case patient in the Low-PF cohort compared to High-PF. A small portion of patients (n = 14) failed treatment strategies and went on to receive CLBP-surgery despite not having surgical indications at baseline. Median healthcare charges from the 3-month period surrounding date of surgery were $59,809 (IQR: $46,057-85,484).ConclusionsCumulative Year-1 healthcare charges were almost 3-fold higher in Low-PF patients compared to High-PF. The mixed effects regression model estimated cumulative 2-year charges to be over 2-fold higher for Low-PF compared to High-PF, in the base-case patient. There were significantly higher rates of all-cause inpatient, outpatient, and ED visits in the year following diagnosis of mechanical CLBP for Low-PF patients. Despite receiving treatment, some patients went on to receive costly surgical procedures over the course of follow-up.

Project description:Objective: Chronic pain is a major problem in patients with spinal cord injury (SCI). According to different studies, approximately 70% of patients with SCI experience persistent pain. Although previous gene expression profiling studies have been conducted in animal models, gene expression profiling study in human whole blood has not been reported yet. The objective of this study was to define the gene expression profile of neuropathic pain in spinal cord injured patients. Materials and Methods: We performed gene expression analysis including 20.000 genes using Affymetrix GeneChip® Primeview™ Human Gene Expression Arrays. For confirmation of expression levels of selected genes, we performed real time polymerase chain reaction. We gathered samples from periferic blood mononuclear cells. Data of twelve patients with intractable neuropathic pain was compared with thirteen patients who don’t have pain. All patients have complete injuries with a level of injury above T5. Results: A total of 16 differentially expressed genes including 9 up-regulated and 7 down-regulated were obtained with a cut-off degree at 4 fold change. EIF1AY, RPS4Y1, DDX3Y, RPL31, ETS1, KLF3, JUN, CYorf15B, and ERAP2 were in up-regulated and HLA-C, XIST, C4BPA, FAM118A, ZNF506, OVOS2, and C1D were in down-regulated group. KEGG pathway database showed that 14.6% of genes were enriched in the nodes of immune system. Real time polymerase chain reaction analyses did not increase to statistically significant levels for confirmation of gene expression analyze results. Conclusions: Considering these data, findings of this first gene expression study in humans with SCI might provide valuable information for future targets for understanding neuropathic pain pathogenesis. The results of gene expression analyses were not confirmed by real time polymerase chain reaction. Studies with larger sample size are needed for confirmation. This is a cross-sectional study with a control group. Patients were divided into two groups according to intractable neuropathic pain existence.There were 12 patients in group A (Patients with pain) and 13 patients in control group.

Project description:Background and aimNeuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system. Pharmacological treatments for neuropathic pain often fail despite following guidelines. Interdisciplinary Pain Rehabilitation Programs (IPRP) are an effective intervention for chronic pain conditions. Little research has investigated whether IPRP can benefit patients with chronic neuropathic pain compared to other chronic pain conditions. This study assesses the real-world effects of IPRP on patients with chronic neuropathic pain compared to non-neuropathic patients using Patient-Reported Outcome Measures (PROMs) available in the Swedish Quality Registry for Pain Rehabilitation (SQRP).MethodsA neuropathic group of patients (n = 1,654) were identified in two steps. This group was compared to a non-neuropathic group (n = 14,355) composed of common diagnoses (low back pain, fibromyalgia, whiplash associated disorders, and Ehlers-Danlos Syndrome) in relation to background variables, three overall outcome variables, and mandatory outcome variables (pain intensity, psychological distress symptoms, activity/participation aspects and health-related quality of life variables). Of these patients 43-44% participated in IPRP.ResultsAt assessment, the neuropathic group reported significantly (with small effect sizes (ES)) more physician visits the previous year, older age, shorter pain durations, and less spatial extent of the pain (moderate ES). Moreover, for the 22 mandatory outcome variables, we found only clinically insignificant differences according to ESs between the groups. For patients participating in IPRP, the neuropathic group displayed equal or in some cases slightly superior results compared to the non-neuropathic group.Discussion and conclusionAfter assessing the real-world effects of IPRP, this large study found that neuropathic pain patients can benefit from the IPRP intervention. Both registry studies and RCTs are needed to better understand which patients with neuropathic pain are most suitable for IPRP and to what extent special considerations need to be made for these patients within the framework of IPRP.

Dataset Information

Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients.

Background

Methods

Results

Conclusion

Level of evidence

Publications

Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets